← All compoundsNMN
See NMN →See Nicotinamide Riboside →
/ comparison
NMN
vs
Nicotinamide Riboside
Side-by-side comparison of mechanism, research, dosing, side effects, and pricing.
metabolite
NMN
NAD+ precursor. Direct biosynthetic precursor.
Cheapest
$50.25
250mg at AMP Peptides
metabolite
Nicotinamide Riboside
NAD+ precursor. Vitamin B3 derivative.
Cheapest
$62.58
250mg at Solution Peptides
/ research scoring
Research base
NMN
Research Maturity★★★★☆
Evidence Strength★★★★☆
Multiple human trials, growing research base.
Nicotinamide Riboside
Research Maturity★★★★☆
Evidence Strength★★★★☆
Multiple human trials.
/ mechanism
How they work
NMN
Direct NAD+ biosynthetic precursor.
Nicotinamide Riboside
NAD+ biosynthetic precursor via different pathway than NMN.
/ research dosing
Protocols compared
NMN
Range: 250-1000 mg/day (most common: 500mg/day)
Frequency: Once daily, AM
Route: Oral capsule or sublingual
AM dosing common. Sublingual may have higher bioavailability than swallowed capsule. Doses up to 1200mg/day used in trials.
Nicotinamide Riboside
Range: 300-1000 mg/day (most common: 500-600mg/day)
Frequency: Once daily, AM
Route: Oral
Nicotinamide riboside. Niagen brand widely studied. AM dosing standard. Multiple weeks needed for NAD+ pool elevation.
/ side effects & timeline
What to expect
NMN
Side effects
Generally well-tolerated.
Timeline
8-12 weeks
Nicotinamide Riboside
Side effects
Generally well-tolerated.
Timeline
8-12 weeks
/ pricing
Price comparison
NMN
Lowest price$50.25 (250mg)
Min $/mg$0.10/mg
Avg $/mg$0.26/mg
Max $/mg$0.50/mg
Nicotinamide Riboside
Lowest price$62.58 (250mg)
Min $/mg$0.13/mg
Avg $/mg$0.32/mg
Max $/mg$0.54/mg
/ which to pick
The honest verdict
Pick NMN if: Standard standalone supplementation.
Pick Nicotinamide Riboside if: Standalone supplementation.
Why not both? Some researchers run them together. Check our Interaction Matrix to see if these compounds synergize or work independently.
FOR RESEARCH USE ONLY. Both compounds are intended for laboratory research and not for human consumption.
